The clinical significance of hematocrit values before and after percutaneous coronary intervention.

[1]  C. Reid,et al.  Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. , 2008, Cardiovascular revascularization medicine : including molecular interventions.

[2]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[3]  A. Kastrati,et al.  Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.

[4]  J. Gore,et al.  Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction? , 2007, Circulation.

[5]  J. Eikelboom,et al.  Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk , 2007, Clinical cardiology.

[6]  J. Boura,et al.  Impact of Acute Blood Loss Anemia and Red Blood Cell Transfusion on Mortality after Percutaneous Coronary Intervention , 2007, Clinical cardiology.

[7]  Thomas W. Wallace,et al.  The Challenge of Defining Bleeding Among Patients with Acute Coronary Syndromes , 2007, Clinical cardiology.

[8]  S. Steinhubl,et al.  Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. , 2007, American heart journal.

[9]  A. Lincoff,et al.  Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. , 2007, The American journal of cardiology.

[10]  S. Steinhubl,et al.  Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. , 2006, The New England journal of medicine.

[11]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[12]  J. Gore,et al.  Bleeding complications in patients with anemia and acute myocardial infarction. , 2005 .

[13]  L. Goodnough,et al.  Anemia of chronic disease. , 2005, The New England journal of medicine.

[14]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[15]  J. J. Griffin,et al.  Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. , 2004, Journal of the American College of Cardiology.

[16]  Samin K. Sharma,et al.  Anemia is an independent predictor of mortality after percutaneous coronary intervention. , 2004, Journal of the American College of Cardiology.

[17]  G. Breithardt,et al.  Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. , 2003, European heart journal.

[18]  N. Weissman,et al.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.

[19]  M. Bell,et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.

[20]  R. Califf,et al.  Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction , 1997 .

[21]  P. Levy,et al.  Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. , 1996, The Journal of trauma.

[22]  Thomas J. Ryan,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). , 1993, Journal of the American College of Cardiology.

[23]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[24]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[25]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[26]  R. Califf,et al.  Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.

[27]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .